Fulcrum Therapeutics, INC 8-K filings

Fulcrum Therapeutics announced the appointment of Alan Musso as Principal Accounting Officer, effective August 7, 2026, following the departure of Greg Tourangeau.

Fulcrum Therapeutics stockholders elected three directors, approved executive compensation, and ratified auditors.

Fulcrum Therapeutics implements a restructuring plan, including executive retention bonuses and the departure of its principal accounting officer.

Fulcrum Therapeutics announces a significant restructuring, including an 85% workforce reduction and discontinuation of a sickle cell disease drug, while simultaneously initiating a comprehensive review of strategic alternatives.

Fulcrum Therapeutics announced the termination of its license agreement with CAMP4 Therapeutics, the appointment of Josh Lehrer to its Board of Directors, and reported Q1 2026 financial results, including positive clinical data for pociredir.

Fulcrum Therapeutics announced positive 12-week results from its Phase 1b PIONEER trial for sickle cell disease and extended its cash runway into 2029.

Fulcrum Therapeutics reports promising Phase 1b data for its sickle cell disease drug pociredir and a robust cash position extending into 2029.

Fulcrum Therapeutics announced the pricing of an upsized public offering of common stock and pre-funded warrants, expecting to raise $175.0 million in gross proceeds.

Fulcrum Therapeutics announced positive initial results from the 20 mg dose cohort of its Phase 1b PIONEER trial for pociredir in sickle cell disease, demonstrating robust fetal hemoglobin induction and a favorable safety profile.

Fulcrum Therapeutics announced its third quarter 2025 financial results and provided an update on its clinical programs, including encouraging data from the PIONEER trial for sickle cell disease.

Fulcrum Therapeutics presented updated clinical data for its lead candidate, pociredir, showing robust efficacy and favorable tolerability in sickle cell disease patients.

Fulcrum Therapeutics announced promising Phase 1b clinical trial results for its sickle cell disease drug candidate, pociredir, showing significant increases in fetal hemoglobin and improved safety, alongside an extended cash runway into 2028.

Fulcrum Therapeutics, Inc. announced the results of its 2025 Annual Meeting, where stockholders re-elected three Class III directors, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor.

Fulcrum Therapeutics reports enrollment completion in the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease and provides a financial update for Q1 2025.

MyoKardia, now a subsidiary of Bristol-Myers Squibb, has terminated its collaboration and license agreement with Fulcrum Therapeutics, effective June 26, 2025.

Fulcrum Therapeutics reports financial results for Q4 and full year 2024, highlighting a strong cash position and advancements in their sickle cell disease program.

Fulcrum Therapeutics expects to report approximately $240 million in cash, cash equivalents, and marketable securities as of December 31, 2024, and anticipates a transformational year in 2025.

Fulcrum Therapeutics received notice from Sanofi that they are terminating their collaboration and license agreement for losmapimod, effective April 17, 2025, ending potential milestone payments and royalties.

Fulcrum Therapeutics announced its third quarter 2024 financial results, highlighting progress in its sickle cell disease program and a cash runway into at least 2027.

Fulcrum Therapeutics has announced the resignation of director James J. Collins and the appointment of Rachel King as a new independent director, effective November 12, 2024.

Fulcrum Therapeutics is restructuring its research and development efforts, leading to a workforce reduction and a focus on key programs.

Fulcrum Therapeutics' Phase 3 REACH trial for losmapimod in FSHD did not meet its primary endpoint, leading to the suspension of the program.

Fulcrum Therapeutics exchanged common stock for pre-funded warrants with two institutional investors, allowing them to purchase shares at a nominal price.

Fulcrum Therapeutics announced its second quarter 2024 financial results, highlighted by a significant increase in revenue due to a collaboration with Sanofi, and provided an update on its clinical programs.

Fulcrum Therapeutics increased its board size, appointed a new director, and held its 2024 annual meeting of stockholders.

Fulcrum Therapeutics has entered into a collaboration with Sanofi, granting them exclusive rights to commercialize losmapimod outside the U.S. for an upfront payment of $80 million and potential milestones up to $975 million.

Fulcrum Therapeutics announced its 2023 financial results and provided updates on its clinical programs, including the Phase 3 trial for losmapimod and the restarted Phase 1b trial for pociredir.